Momelotinib
Ojjaara · JAK/ACVR1 inhibitor
2023 myelofibrosis JAK inhibitor.
CSF1R tyrosine kinase inhibitor
Romvimza · CSF1R TKI
CSF1R tyrosine kinase inhibitor · approved 2025 · 5 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A clean-kidney targeted TKI — watch the CPK, not the nephron.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
No clinically significant direct nephrotoxicity was identified in the pivotal MOTION phase 3 trial. There is no recognized signature renal lesion (no ATN, AIN, TMA, or glomerular injury attributable to the drug). The kidney-relevant practical issue is interpretive: the dominant laboratory abnormality is treatment-emergent creatine phosphokinase (CPK) elevation — grade 3/4 in 8/83 (10%) of vimseltinib patients in MOTION — together with peripheral/periorbital edema, either of which can perturb serum creatinine or muscle-derived markers without true GFR loss. Renal-specific events were not reported as a notable safety signal.Source: MOTION phase 3 (Gelderblom et al., Lancet 2024; PMID 38843860): the only grade 3/4 TEAE occurring in >5% of vimseltinib patients was increased blood CPK (10%); no clinically significant direct nephrotoxicity reported.
CPK elevations, edema, and any linked creatinine change emerge early, typically within the first 1-2 twenty-eight-day cycles (through ~day 56).
Distilled from: “CPK elevations and edema emerge early, typically within the first 1-2 treatment cycles (28-day cycles); any associated creatinine change tracks with these rather than following a delayed structural pattern.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
In the phase 3 MOTION trial (n=83) the predominant grade 3/4 laboratory abnormality was increased blood creatine phosphokinase (10%); CSF1R inhibition characteristically produces asymptomatic creatinine/muscle-enzyme elevations (pseudo-AKI) rather than true GFR loss or structural injury. PMID 38843860 (opens PubMed in a new tab)
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Vimseltinib is an oral, switch-control tyrosine kinase inhibitor designed to selectively and potently inhibit the colony-stimulating factor 1 receptor (CSF1R). In tenosynovial giant cell tumor (TGCT), a translocation drives CSF1 overexpression, recruiting and sustaining CSF1R-bearing macrophage-lineage cells that form the tumor mass. By blocking CSF1R signaling, vimseltinib depletes this tumor-associated macrophage compartment, producing tumor regression and functional/symptomatic improvement. Its high kinase selectivity (sparing KIT, FLT3, and most class III/V RTKs) underlies a narrow off-target profile relative to less selective CSF1R/KIT inhibitors.
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Vasculature / Endothelium
Glomerular & peritubular capillaries
5 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 549 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
1 of 549 reports
Reported with hospitalization
21 of 549 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Vimseltinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Ojjaara · JAK/ACVR1 inhibitor
2023 myelofibrosis JAK inhibitor.
Alecensa · ALK TKI
Creatinine rise via reduced tubular secretion.
Bosulif · BCR-ABL TKI
Reversible eGFR decline.
Zykadia · ALK TKI
GI-driven prerenal AKI.
Gavreto · RET inhibitor
Hypertension; rare AKI.
Inluriyo · Oral selective estrogen-receptor degrader (SERD)
2025 brain-penetrant oral SERD; renally benign — the only wrinkle is the benign abemaciclib creatinine rise in the combo.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.